Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 21 December 2020, 19:00 HKT/SGT
Share:
China Medical System (00867.HK) MSCI-ESG Rating Upgraded to AA, Reaching Global Level

HONG KONG, Dec 21, 2020 - (ACN Newswire) - Morgan Stanley Capital International (MSCI) issued a report on December 17 upgrading the ESG (Environmental, Social and Governance) Rating for China Medical System Holdings Limited ("China Medical System"), a well-established, innovation-driven specialty pharma with a focus on sales & marketing in China. China Medical System's ESG Rating has been upgraded from "BBB" to "AA", surpassing 88% of companies in the global pharmaceutical industry, symbolizing that the Company has attained a level among its global peers in ESG management.

MSCI recognized China Medical System's outstanding performance in Corporate Governance, Corporate Behavior, Product Safety and Quality, Human Capital Development, and Access to Health Care, noting that the Company "Leads peers in business ethics and talent management practices". MSCI also gave a positive assessment of the Company's Corporate Behavior, "China Medical System has evidence of detailed policies on business ethics and corruption".

There are seven levels of the MSCI-ESG Rating, from the highest to the lowest are AAA, AA, A, BBB, BB, B, and CCC. Among them, companies with AA or AAA ratings are considered to be industry leaders in managing the most significant ESG risks and opportunities. This year, China Medical System's MSCI-ESG Rating has been upgraded by three levels, from BB to AA.

According to the Company, "Receiving the AA ESG Rating from MSCI reflected China Medical System's long-term focus and resource investment on ESG management and information disclosure, and affirmed the Company's compliance focus and solid business practices. In recent years, with leadership from the Board of Directors, the Company's ESG-related policies have increasingly improved, ESG practices are more standardized, and ESG management is constantly refined.

"In the future, through self-challenge and transcendence, China Medical System will continuously pursue higher corporate governance goals. The Company will continuously regard innovation as its driving force, to fulfill the unmet medical needs, and contribute to the integrated development of society, the environment, and civilization."



Topic: Rating Report
Source:

Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Latest Press Releases
Redsun Services Acquires 80% Equity Interest in Each of Gaoli Property and Jiangsu Gaoli Meijia for RMB73.54 Million  
Apr 20, 2021 22:08 HKT/SGT
Edvantage Group (0382.HK) 2021 Interim Results Exceeding Expectations With Adjusted Net Profit Increased by 32.5% YoY to Approximately RMB199.9 Million  
Apr 20, 2021 21:35 HKT/SGT
Torum Closes Million Dollars Private Round to Create The First Social Media Platform with NFT & DeFi Innovations  
Apr 20, 2021 21:00 HKT/SGT
Moonstake Celebrates Our First Anniversary - World's Top 10 Staking Providers in One Year  
Apr 20, 2021 20:00 HKT/SGT
HKTDC's debut Lifestyle ShoppingFest opens 28 April  
Apr 20, 2021 19:00 HKT/SGT
Bina Puri wins RM183 million building job in Nepal  
Apr 20, 2021 14:00 HKT/SGT
Moonstake Wallet Now Supports Staking of ORBS  
Apr 20, 2021 11:05 HKT/SGT
TEC named one of Asia's fastest growing companies by the Financial Times   
Apr 20, 2021 10:18 HKT/SGT
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease   
Apr 20, 2021 08:23 HKT/SGT
Honda Exhibits the World Premiere of the "Honda SUV e:prototype" at Auto Shanghai 2021  
Apr 19, 2021 23:01 HKT/SGT
More Press release >>
 Events:
More >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: